Prosecution Insights
Last updated: November 12, 2026
Application No. 18/720,787

PROCESS FOR PRODUCING PROPOFOL

Non-Final OA §103
Filed
Jun 17, 2024
Priority
Dec 17, 2021 — FR FR2113836 +1 more
Examiner
PARSA, JAFAR F
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pcas
OA Round
1 (Non-Final)
87%
Grant Probability
Favorable
1-2
OA Rounds
96%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
1100 granted / 1261 resolved
+27.2% vs TC avg
Moderate +9% lift
Without
With
+8.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
23 currently pending
Career history
1282
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-19 are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al (US 2013/0072573 A1) in view of Sharma et al (US 2023/0174444 A1). Applicants’ claimed invention is directed to a process for preparing 2,6-diisopropyl phenol comprising a step of decarboxylation of 4-hydroxy-3,5-diisopropylbenzoic acid or a salt thereof in an aqueous medium under pressure. Jain discloses a process for preparing highly pure 2,6-diisopropylphenol (Propofol) by decarboxylating 4-hydroxy-3,5-diisopropylbenzoic acid (Formula III) at an elevated temperature of 1200 C to 1600 C in the presence of a catalyst and an organic high boiling solvent like ethylene glycol [0029] and [0031]-[0032]. Sharma teaches an improved decarboxylation process for the same starting material using a heterocyclic base catalyst, executed under solvent free or aromatic hydrocarbon solvent conditions [0035]-[0038]. Crucially, Sharma discloses the post-reaction extraction and processing of the reaction mass using an aqueous medium (water) followed by fractional distillation of the product under reduced pressure of 1-5 Mbar [0052]. Differences between prior art and claims 1: The prior art references perform the actual bond-cleaving decarboxylation reaction in either high-boiling organic solvent (Jain et al) or under solvent-free/organic conditions (Sharma et al). Water is used by Sharma solely as a post-reaction quenching or washing medium, and pressure manipulation in Sharma is down-regulated to a vacuum (reduced pressure). Claim 1 performs the decarboxylation step itself inside an aqueous medium under super atmospheric pressure. Obviousness and Motivation: It would have been obvious to a person of ordinary skill in the art, prior to the effective filling date of the claimed invention optimizing the process of Jain to look the teachings of Sharma. Sharma notes that avoiding high-boiling organic solvent (like the ethylene glycol of Jain) is highly desirable because organic solvents impact the quality of the final active pharmaceutical ingredient (API) and requires extensive workup [0048]. A PHOSITA, seeking to eliminate toxic organic solvent streams and simplify the extraction phase, would be motivated to test water the universal green solvent as the direct fluid reaction medium. Because water vaporizes rapidly at the required decarboxylation temperatures (1200 C-1600 C as taught by both Jain and Sharma). A PHOSITA utilizing basic thermodynamic and chemical engineering principles would recognize that the reaction must be conducted under super atmospheric pressure to maintain the water in a liquid state. Thus, combining the reaction steps of Jain with the aqueous processing hints of Sharma to form a pressurized aqueous reaction system is merely the predictable application of known engineering practices to achieve a known objective (solvent reduction). Regarding claims 2, 3, 10, 11, 12, 13, Jain explicitly teaches that the decarboxylation catalyst is a mineral base, specifically an alkali metal hydroxide selected from sodium hydroxide or potassium hydroxide [0029], [0031]. Furthermore, the working Example 2 of Jain explicitly react 0.45 moles of benzoic acid derivative with 1.03 moles of sodium hydroxide pellets, establishing an exact concentration of 2.28 molar equivalents of base [0041]. Sharma teaches using an organic base range reaching down to 0.5 equivalents [0053]. Differences between prior art and claims: None. The chemical identities (mineral base, alkali metal hydroxide) and the claimed concentration ranges (0.1 to 3 equivalents in claim 3, 12; 0.5 to 2.5 equivalents in claim 13) literally encompass the exact parameters disclosed in working Example 2 of Jain (2.28 equivalents) and the examples of Sharma (0.5 equivalents). Obviousness and Motivations: O0174444nce the PHOSITA modifies the reaction medium to pressurized water as articulated in claim 1, it is entirely obvious to select the exact catalysts and concentration ranges already optimized and proven successfully by Jain and Sharma. An alkali metal hydroxide like NaOH is highly water-soluble, making it a naturally obvious catalytic choice for an aqueous-phase reaction. The optimization of a reagent range (swapping between 0.1-3 or 0.5-2.5 equivalents) represents routine experimental scaling within the competence of a PHOSITA. Regarding claims 4, 5, 6, 14, 15 and 18, both Jain and Sharma perform their reactions in standard batch environments (e.g. round-bottom flasks and stirred reactors) over distinct periods (7 hours for Jain; 1.5 to 2 hours for Sharma [0052]. Jain operates at temperatures of 120-1600 C [0031]. Sharma operates at temperature of 120-1700 C, preferably 145-1550 C [0036]. Differences between prior art and claims: The batch claims specify operation within explicit pressure windows (0.2-1.2 MPa in claim 5; 0.25-1.0 MPa in claim 14) and temperature windows (120-2000 C in claim 6; 125-1900 C in claim 15), or combination thereof (claim 18). Obviousness and Motivations: Both references establish the baseline reaction format as a batch process, rendering claim 4 obvious. Regarding the specific temperature window (e.g. 120-2000 C) these directly overlap with 120-1600 C range of Jain and the 120-1700 C range of Sharma. The specific pressure limitations (0.2 to 1.2 MPa) is an inherent, predictable consequence of running the reaction inside a closed batch autoclave using water at those identical temperatures. For instance, according to standard steam tables liquid water at 1200 C exerts a vapor pressure of approximately 0.2 MPa, and at 1800 C exerts approximately 1.0 MPa. A PHOSITA would be motivated to operate within these exact closed-vessel pressure constraints simply to maintain the liquid state of the aqueous reaction medium at the established working temperatures of the prior art. Regarding claims 7, 8, 9, 16, 17 and 19, Jain and Sharma teach batch synthesis parameters for Propofol. Sharma specifically nots that a core goal of the industry is to develop a time-efficient and cost-effective process that accelerates the reaction process substantially to achieve considerable cost savings because of shorter facility use [0016], [0040]. Differences between prior art and claims: The prior art uses batch vessels. The claims define executing the aqueous pressurized decarboxylation within a continuous flow regime at elevated pressures (1.0-2.5 MPa / 1.5-2.0 MPa) at elevated temperatures (160-2200 C / 170-2100 C). Obviousness and Motivation: Converting a known chemical reaction from a batch mode to a continuous flow mode represents a routine commercial scaling practice in modern chemical engineering. Driven by the motivation of Sharma to drastically accelerate reaction velocity and reduce facility residency times, a PHSITA wound recognize that continuous flow microreactors or plug-flow configurations maximize heat and mass transfer. Because continuous flow lines experience dynamic fluid movement, higher system pressures (1.0-2.5 MPa) are standardly applied to prevent outgassing and bubbling of the solvent stream. The associated temperature increases (up to 2200 C) represents a predictable optimization step to decrease residence time from hours to minutes, which falls squarely within the routine skill of an engineer implementing the time-saving goals explicitly called for by Sharma. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAFAR F PARSA whose telephone number is (571)272-0643. The examiner can normally be reached M-F 10:00 AM-6:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAFAR F PARSA/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Jun 17, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12789158
Reactor and Process for the Hydrogenation of Carbon Dioxide
3y 2m to grant Granted Nov 10, 2026
Patent 12790457
MONOMER PRODUCTION SYSTEM AND MONOMER PRODUCTION METHOD
2y 11m to grant Granted Nov 10, 2026
Patent 12780768
PROCESS FOR PREPARING METHANOL
3y 7m to grant Granted Nov 03, 2026
Patent 12780790
METHOD FOR PRODUCING TETRAHYDROFURAN, GAMMA-BUTYROLACTONE, OR 1,4-BUTANEDIOL
2y 10m to grant Granted Nov 03, 2026
Patent 12767622
METHOD FOR CHLORINATING AROMATIC COMPOUND
3y 2m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
87%
Grant Probability
96%
With Interview (+8.9%)
Low
PTA Risk
Based on 1261 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month